**Appendix S1**

Appendices - Search strategy in the review

PubMed

("Ovarian Neoplasms"[Mesh] OR "ovarian cancer"[All Fields] OR "oophoroma"[All Fields] OR "carcinoma of ovary"[All Fields] OR "cervi\*"[Title/Abstract] OR "uterine neck"[Title/Abstract] OR "neck of uterus"[Title/Abstract] OR "Cervix cancer"[All Fields] OR "Cervical cancer"[All Fields] OR "Cancer Cervix"[All Fields] OR "Cancer of the cervix" [All Fields] OR "cervix tumors"[All Fields] OR "endometrial cancer"[MeSH] OR "endometrium"[Title/Abstract] OR "uterus cancer"[Title/Abstract] OR "uterine cancer"[Title/Abstract] OR "corpus uteri cancer"[Title/Abstract] OR "endometrial cancer"[All Fields] OR "endometrial carcinoma"[All Fields] OR "endometrial neoplasia"[All Fields] OR "endometrial tumor"[All Fields] OR "endometrial neoplasm"[All Fields] OR "endometrial maligna"[All Fields] OR "uterine cancer"[All Fields] OR "uterine carcinoma"[All Fields] OR "uterine neoplasia"[All Fields] OR "uterine tumor"[All Fields] OR "uterine neoplasm"[All Fields] OR "uterine maligna"[All Fields]) AND ("survival rate"[Title/Abstract] OR "survival rates"[Title/Abstract] OR "survival analysis"[Title/Abstract] OR "survival analyses"[Title/Abstract] OR "survival\*"[Title/Abstract] OR "survival rate"[Mesh] OR "survival analysis"[Mesh] OR "survival"[Mesh]) AND ("population-based"[Title/Abstract] OR "cancer registry"[Title/Abstract])

Web of Science

(TS=“Ovarian Neoplasms” OR TS=“ovarian cancer” OR TS=“oophoroma” OR TS=“carcinoma of ovary” OR TS=“Cervix cancer” OR TS=“Cervical cancer” OR TS=“Cancer Cervix” OR TS=“cervix tumors” OR TS=“endometrial cancer” OR TS=“uterus cancer” OR TS=“corpus uteri cancer” OR TS=“endometrial carcinoma” OR TS=“endometrium” OR TS=“endometrial neoplasia” OR TS=“endometrial tumor” OR TS=“endometrial neoplasm” OR TS=“endometrial maligna” OR TS=“uterine cancer” OR TS=“uterine carcinoma” OR TS=“uterine neoplasia” OR TS=“uterine tumor” OR TS=“uterine neoplasm” OR TS=“uterine maligna” )AND (TS=”survival rate” OR TS=”survival rates” OR TS=“survival analysis” OR TS=“survival analyses” OR TS=survival\*) AND (TS=”population-based” OR TS=”cancer registry”)

EMBASE

('neoplasm'/exp OR 'neoplasm' OR neoplas\* OR tumor\* OR tumour\* OR cancer\* OR hamartoma\* OR incidentaloma\* OR metasta\* OR carcinoma\* OR sarcoma\* OR spheroid\* OR adenocarcinoma\* OR adenosarcoma\*) AND ((('uterus'/exp OR 'uterus' OR 'uterine' OR endometri\* OR 'uteri' OR 'ovary' OR 'ovary'/exp OR ovary OR ovarian OR 'cervix'/exp OR 'cervix' OR cervi\* OR 'uterine'/exp OR uterine) AND ('neck'/exp OR neck) OR 'neck'/exp OR neck) AND of AND ('uterus'/exp OR uterus) OR 'cervix'/exp OR cervix OR cervical) AND ((((('survival rate'/exp OR 'survival rate' OR 'survival analysis'/exp OR 'survival analysis' OR 'survival' OR 'survival'/exp OR survival) AND rate OR 'survival'/exp OR survival) AND rates OR 'survival'/exp OR survival) AND ('analysis'/exp OR analysis) OR 'survival'/exp OR survival) AND analyses OR survival\*) AND ('population based' OR 'cancer registry'/exp OR 'cancer registry')

SinoMed

(" Ovarian cancer "[all fields] OR "ovarian tumor "[all fields] OR" ovarian Neoplasms"[all fields] OR "ovarian cancer "[all fields] OR" ovarian tumor "[Mesh] OR "endometrial cancer "[all fields] OR "Endometrial Neoplasms"[all fields] OR "Endometrial Neoplasms"[all fields] OR "endometrial neoplasms "[all fields] OR" endometrial cancer "[all fields] OR "endometrial cancer "[all fields] OR" endometrial cancer "[all fields] or "endometrial neoplasms "[Mesh] OR "Cervical Neoplasms"[all fields] OR" cervical neoplasms "[all fields] OR "cervical neoplasms "[all fields] OR" cervical neoplasms "[all fields] OR "cervical neoplasms "[all fields] OR" Cervical neoplasms "[Mesh]) AND (" Survival Rate"[all fields] OR" survival analysis "[all fields] OR" % survival rate "[all fields] OR" survival rate "[all fields] OR" survival rate "[Mesh]) AND (" population "[all fields] OR "population-based"[all fields] OR "Tumor registry"[all fields] OR "cancer Registry "[all fields] OR" Cancer Registry "[all fields] OR "cancer registry"[all fields] or "Registry "[Mesh])

**Supplementary Table S1**: PRISMA Checklist. PRISMA Checklist filled in for this review

| **Section and Topic** | **Item #** | **Checklist item** | Location where item is reported |
| --- | --- | --- | --- |
| **TITLE** | | |  |
| Title | 1 | Identify the report as a systematic review. | Title |
| **ABSTRACT** | | |  |
| Abstract | 2 | See the PRISMA 2020 for Abstracts checklist. | Page 1 and 2 manuscript |
| **INTRODUCTION** | | |  |
| Rationale | 3 | Describe the rationale for the review in the context of existing knowledge. | Page 3 manuscript |
| Objectives | 4 | Provide an explicit statement of the objective(s) or question(s) the review addresses. | Page 3 manuscript |
| **METHODS** | | |  |
| Eligibility criteria | 5 | Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses. | Page 3 manuscript |
| Information sources | 6 | Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted. | Page 3 manuscript |
| Search strategy | 7 | Present the full search strategies for all databases, registers and websites, including any filters and limits used. | Supplement Appendices 1 |
| Selection process | 8 | Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process. | Page 3 manuscript, and  Figure 1 |
| Data collection process | 9 | Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process. | Page 3 manuscript |
| Data items | 10a | List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect. | Page 3 manuscript |
| 10b | List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information. | n.a. |
| Study risk of bias assessment | 11 | Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process. | Page 4 manuscript |
| Effect measures | 12 | Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results. | n.a. |
| Synthesis methods | 13a | Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)). | n.a. |
| 13b | Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions. | Page 4 manuscript |
| 13c | Describe any methods used to tabulate or visually display results of individual studies and syntheses. | Page 4 manuscript |
| 13d | Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used. | n.a. |
| 13e | Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression). | n.a. |
| 13f | Describe any sensitivity analyses conducted to assess robustness of the synthesized results. | n.a. |
| Reporting bias assessment | 14 | Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases). | n.a |
| Certainty assessment | 15 | Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome. | n.a |
| **RESULTS** | | |  |
| Study selection | 16a | Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram. | Figure 1 |
| 16b | Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded. | Supplement Table 12 |
| Study characteristics | 17 | Cite each included study and present its characteristics. | Supplement Table 2 |
| Risk of bias in studies | 18 | Present assessments of risk of bias for each included study. | n.a |
| Results of individual studies | 19 | For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots. | Figure 2-4, Table 1-6 |
| Results of syntheses | 20a | For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies. | n.a |
| 20b | Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect. | Supplement Table 3-11 |
| 20c | Present results of all investigations of possible causes of heterogeneity among study results. | n.a |
| 20d | Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results. | n.a. |
| Reporting biases | 21 | Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed. | n.a. |
| Certainty of evidence | 22 | Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed. | n.a |
| **DISCUSSION** | | |  |
| Discussion | 23a | Provide a general interpretation of the results in the context of other evidence. | Page 20 and 21 manuscript |
| 23b | Discuss any limitations of the evidence included in the review. | Page 22 manuscript |
| 23c | Discuss any limitations of the review processes used. | Page 22 manuscript |
| 23d | Discuss implications of the results for practice, policy, and future research. | Page 22 manuscript |
| **OTHER INFORMATION** | | |  |
| Registration and protocol | 24a | Provide registration information for the review, including register name and registration number, or state that the review was not registered. | n.a |
| 24b | Indicate where the review protocol can be accessed, or state that a protocol was not prepared. | n.a |
| 24c | Describe and explain any amendments to information provided at registration or in the protocol. | n.a |
| Support | 25 | Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review. | n.a |
| Competing interests | 26 | Declare any competing interests of review authors. | Page 22 manuscript |
| Availability of data, code and other materials | 27 | Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review. | n.a |

**Supplementary Table S2**: Characteristics of included studies

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author** | **Year** | **Title** | **Data source** | **ICD** | **DCO exclusion** | **Number of cases of cervical cancer** | **Number of cases of uterine cancer** | **Number of ovarian cancer cases** |
| Wang Y, Wang J, Xu Y, et al | 2022 | Survival trend of cervical cancer in Qidong city of Jiangsu province from 1977 to 2016 | Qidong City Center for Disease Control and Prevention | ICD-10 | no | 1546 | unreported | unreported |
| Shimin D, Nan L, Yan L, et al | 2014 | Analysis of survival in major malignances during 2008－2013 in Jiulongpo avea of Chongqing | Jiulongpo District Center for Disease Control and Prevention | unreported | yes | 252 | 125 | 166 |
| Gong W, Luo S, Hu R, et al | 2014 | Analysis of survival rate of breast, cervical, and ovarian cancer patients during 2005-2010 in Zhejiang province, China | Zhejiang Provincial Center for Disease Control and Prevention | ICD-10 | yes | 4752 | unreported | 2046 |
| Li Y, Lv Y, Lin W, et al | 2017 | Survival analysis of patients with malignant tumors in Sihui city between 1987 and 2009 | Sihui City Cancer Registry | ICD-10/ICD-O-3 | no | unreported | unreported | unreported |
| Zhou J, Su X, Li L, et al | 2020 | Survival rate among the main cancer patients in three countys of GuiZhou province,2013－2015 | Guizhou Provincial Center for Disease Control and Prevention | ICD-10 | no | 354 | unreported | unreported |
| Zhang W, Wang L | 2021 | Analysis of cancer incidence and survival in Anshan City from 2008 to 2017 | Anshan City Center for Disease Control and Prevention | ICD-10 | no | 2202 | 918 | 947 |
| Han X, Huang C, Zhao J, et al | 2014 | Incidence and survival analysis of cervical cancer patients among permanent residents in Yangpu district of Shanghai during 2002－2012 | Shanghai Yangpu District Center for Disease Control and Prevention | ICD-10/ICD-O-2 | no | 628 | unreported | unreported |
| Xiang Y, Jin F, Chen H, et al | 1996 | An analysis of survival rate of patients with malignancy in urban district of Shanghai from 1988 to 1991 | Shanghai Cancer Registry | ICD-9 | yes | 612 | 590 | 183 |
| Wang Q, lin X, Wang R, et al | 2001 | An analysis of relative survival rate in patients with malignancy in Tianjin | Tianjin Cancer Registry | ICD-9 | unreported | 955 | 252 | 385 |
| Chiang CJ, Lo WC, Yang YW,et al | 2016 | Incidence and survival of adult cancer patients in Taiwan, 2002-2012 | Taiwan Cancer Registry Database | ICD-O-3 | unreported | 8238 | unreported | unreported |
| Kim IS, Suh I, Oh HC, et al | 1989 | Incidence and survival of cancer in Kangwha County (1983-1987) | Kangwha County Cancer Registry | ICD-9 | unreported | unreported | unreported | unreported |
| Muhamad NA, Kamaluddin MA, Adon MY, et al | 2015 | Survival rates of cervical cancer patients in Malaysia | Malaysian National Cancer Registry and National Health Informatics Centre  (NHIC) | unreported | unreported | 5859 | unreported | unreported |
| Sriamporn S, Swaminathan R, Parkin DM, et al | 2004 | Loss-adjusted survival of cervix cancer in Khon Kaen, Northeast Thailand | Khon Kaen province cancer registry | ICD-9 | unreported | 601 | unreported | unreported |
| Chia KS, Du WB, Sankaranarayanan R, et al | 2001 | Population-based cancer survival in Singapore, 1968 to 1992: an overview | Singapore Cancer Registry | unreported | yes | unreported | unreported | unreported |
| Nandakumar A, Anantha N, Venugopal TC | 1995 | Incidence, mortality and survival in cancer of the cervix in Bangalore, India | Kidwai Memorial Institute of Oncology | ICD-9 | yes | 2423 | unreported | unreported |
| Yeole BB, Kumar AV, Kurkure A, Sunny L | 2004 | Population-based survival from cancers of breast, cervix and ovary in women in Mumbai, India | Mumbai Population Cancer Registry | unreported | yes | 1620 | unreported | 729 |
| Swaminathan R, Selvakumaran R, Esmy PO, et al | 2009 | Cancer pattern and survival in a rural district in South India | Dindigul Ambilikkai Cancer Registry | ICD-10 | yes | 223 | unreported | 26 |
| Fantin R, Santamaría-Ulloa C, Barboza-Solís C | 2020 | Social inequalities in cancer survival: a population-based study using the Costa Rican Cancer Registry | Costa Rican Cancer Registry | ICD-10 | unreported | 1257 | 962 | 514 |
| Arias-Ortiz NE, de Vries E | 2018 | Health inequities and cancer survival in Manizales, Colombia: a population-based study | Manizales population-based Cancer Registry (MCR) | ICD-O-3 | yes | 226 | unreported | unreported |
| Booth CM, Li G, Zhang-Salomons J, Mackillop WJ | 2010 | The impact of socioeconomic status on stage of cancer at diagnosis and survival: a population-based study in Ontario, Canada | Ontario Cancer Registry | ICD-9 | unreported | 1052 | unreported | unreported |
| Pearcey R, Miao Q, Kong W, et al | 2007 | Impact of adoption of chemoradiotherapy on the outcome of cervical cancer in Ontario: results of a population-based cohort study | Ontario Cancer Registry (OCR) | ICD-9 | unreported | 4069 | unreported | unreported |
| Graupera Boschmonar MC, Jiménez Chaviano PJ, Martín García AA, et al | 1999 | Trends in survival rates of cancer in Cuba | National Cancer Registry (NCR） | ICD-O | yes | 1533 | 404 | unreported |
| Sant M, Allemani C, Santaquilani M,et al | 2009 | EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. | 82 cancer registries from 23 European countries | ICD-O-3 | yes | 37622 | 61820 | 60408 |
| Melan K, Janky E, Macni J, et al | 2017 | Epidemiology and survival of cervical cancer in the French West-Indies: data from the Martinique Cancer Registry (2002-2011) | Martinique Cancer Registry | ICD-O-3 | unreported | 306 | unreported | unreported |
| Levi F, Randimbison L, Te VC, et al | 2000 | Trends in survival for patients diagnosed with cancer in Vaud, Switzerland, between 1974 and 1993 | Vaud Cancer Registry | ICD-9 | yes | 314 | 599 | 478 |
| Gafà L, Amendola P, Dardanoni G, et al | 1995 | Cancers of the female genital tract in Ragusa, Sicily | Ragusa Cancer Registry | ICD-9 | unreported | unreported | unreported | unreported |
| Vincerževskiene I, Jasilionis D, Austys D, et al | 2017 | Education predicts cervical cancer survival: a Lithuanian cohort study | Lithuanian Cancer Registry | unreported | unreported | 1866 | unreported | unreported |
| Bjurberg M, Holmberg E, Borgfeldt C, et al | 2019 | Primary treatment patterns and survival of cervical cancer in Sweden: A population-based Swedish Gynecologic Cancer Group Study | Swedish National Cancer Registry (NCR) | ICD-10 | unreported | 2141 | unreported | unreported |
| Brenner H, Hakulinen T | 2008 | Period versus cohort modeling of up-to-date cancer survival | Finnish Cancer Registry | unreported | unreported | 725 | 3370 | 2656 |
| Chakalova G, Dimitrova N, Gavrilov I, et al | 2013 | Cancer burden of breast and gynecological cancers in Bulgaria: epidemiology and clinical aspects | Bulgarian National Cancer Registry | ICD-10 | unreported | unreported | unreported | unreported |
| Waldmann A, Eisemann N, Katalinic A | 2013 | Epidemiology of malignant cervical, corpus uteri and ovarian tumours - current data and epidemiological trends | German Centre for Cancer Registry Data(ZfKD) | unreported | unreported | unreported | unreported | unreported |
| Gondos A, Brenner H, Wabinga H, et al | 2005 | Cancer survival in Kampala, Uganda | The population-based Cancer Registry of Kampala, Uganda | unreported | yes | 285 | unreported | 69 |
| Wabinga H, Ramanakumar AV, Banura C, et al | 2003 | Survival of cervix cancer patients in Kampala, Uganda: 1995-1997 | Kampala Cancer Registry | unreported | yes | 261 | unreported | unreported |
| Dalton SO, Olsen MH, Johansen C, et al | 2019 | Socioeconomic inequality in cancer survival - changes over time. A population-based study, Denmark, 1987-2013 | Danish Cancer Registry | ICD-10 | unreported | unreported | 3417 | 2825 |
| Chen J, Zhu J, Zhang Y | 2006 | An analysis of survival in major malignancies during 1972-2000 in Qidong, China | Qidong City Center for Disease Control and Prevention | ICD-9/10 | unreported | 761 | unreported | 247 |
| Li Y, Huang Q, Lin X, et al | 2013 | Survival rates of malignancies and nasopharyngeal carcinoma during 2003－2005 in Sihui city | Sihui City Cancer Registry | ICD-10 | unreported | 17 | 16 | 17 |
| Arab M, Khayamzadeh M, Mohit M, et al | 2009 | Survival of ovarian cancer in Iran: 2000-2004 | Cancer registry of Iran | unreported | yes | unreported | unreported | 1246 |
| Mahdy NH, Abdel-Fattah M, Ghanem H | 1999 | Ovarian cancer in Alexandria from 1988 to 1997: trends and survival | Alexandria Cancer Registry | unreported | unreported | unreported | unreported | 358 |
| De Angelis R, Sant M, Coleman MP, et al | 2014 | Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study | 107 population-based cancer registries | ICD-O-3 | yes | unreported | unreported | unreported |
| Grann AF, Thomsen RW, Jacobsen JB, et al | 2013 | Comorbidity and survival of Danish ovarian cancer patients from 2000-2011: a population-based cohort study | Danish National Registry | ICD-8/10 | unreported | unreported | unreported | 1540 |
| Dahm-Kähler P, Borgfeldt C, Holmberg E, et al | 2017 | Population-based study of survival for women with serous cancer of the ovary, fallopian tube, peritoneum or undesignated origin - on behalf of the Swedish gynecological cancer group (SweGCG) | National Swedish Cancer Registry (NCR) | ICD-O-3 | unreported | unreported | unreported | 1678 |
| Tretarre B, Molinie F, Woronoff AS, et al | 2015 | Ovarian cancer in France: trends in incidence, mortality and survival, 1980-2012 | French cancer registries | ICD-O-3 | unreported | unreported | unreported | 4615 |
| Brenner H, Stegmaier C, Ziegler H | 1999 | Trends in survival of patients with ovarian cancer in Saarland, Germany, 1976-1995 | the population-based cancer registry of Saarland, Germany | ICD-9 | unreported | unreported | unreported | 2124 |
| Zhou Y, Xiang ZS, Ma JY, et al | 2021 | Survival of cancer patients in Fujian, Southeast China: a population-based cancer registry study | Fujian Provincial Cancer Registry | ICD-O-3/ICD-10 | yes | 887 | 495 | 338 |
| Li H, Du L, Li Q, et al | 2020 | Cancer survival in Haining and Jiashan cancer registry areas of Zhejiang province | Haining city and Jiashan county Cancer Registry | ICD-10 | yes | 538 | 360 | 324 |
| Cheung FY, Mang OW, Law SC | 2011 | A population-based analysis of incidence, mortality, and stage-specific survival of cervical cancer patients in Hong Kong: 1997-2006 | Hong Kong Cancer Registry (HKCaR) | ICD-O | yes | 3807 | unreported | unreported |
| Yagi A, Ueda Y, Kakuda M, et al | 2019 | Epidemiologic and clinical analysis of cervical cancer using data from the population-based Osaka cancer registry | Osaka Cancer Registry | ICD-10 | unreported | 25826 | unreported | unreported |
| Matsuda T, Ajiki W, Marugame T, et al | 2011 | Population-based survival of cancer patients diagnosed between 1993 and 1999 in Japan: a chronological and international comparative study | Miyagi,Yamagata, Niigata, Fukui, Osaka and Nagasaki Cancer Registry | ICD-10 | yes | 6716 | 3259 | 3916 |
| Shin DW, Bae J, Ha J, et al | 2012 | Conditional relative survival of cervical cancer: a Korean National Cancer Registry Study | Korean National Cancer Registry | ICD-O-3 | unreported | 78606 | unreported | unreported |
| Kang MJ, Won YJ, Lee JJ, et al | 2022 | Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2019 | Korea Central Cancer Registry | ICD-O-3 | unreported | 3273 | 3287 | 2888 |
| Chung HH, Jang MJ, Jung KW, et al | 2006 | Cervical cancer incidence and survival in Korea: 1993-2002 | Korea Central Cancer Registry and the Gynecologic Oncology Committee of Korean Society of Obstetrics and Gynecology. | ICD-O | yes | 44182 | unreported | unreported |
| Maláková K, Cabasag CJ, Bardot A, et al | 2022 | Cancer survival in Thailand from 1997 to 2012: assessing the impact of universal health coverage | five Thai population-based cancer regis\_x005f tries, namely Bangkok, Chiang Mai, Khon Kaen, Lampang, and Songkhla. | ICD-10 | yes | 3497(1997-2001), 5631(2002-2006),5527(2008-2012) | unreported | unreported |
| Laudico AV, Mirasol-Lumague MR, Mapua CA, et al | 2010 | Cancer incidence and survival in Metro Manila and Rizal province, Philippines | Philippine Cancer Society-Manila Cancer Registry and Department of Health-Rizal Cancer Registry | unreported | unreported | unreported | unreported | unreported |
| Alawadhi E, Al-Awadi A, Elbasmi A, et al | 2019 | Cancer survival by stage at diagnosis in Kuwait: a population-based study | Kuwait Cancer Registry | ICD-O-3 | yes | 163 | unreported | 221 |
| Gultekin M, Dundar S, Kucukyildiz I, et al | 2017 | Survival of gynecological cancers in Turkey: where are we at? | The National Central Cancer Registry of Turkey | ICD-O-3 | unreported | 351 | 713 | 489 |
| Bielska-Lasota M, Inghelmann R, van de Poll-Franse L, et al | 2007 | Trends in cervical cancer survival in Europe, 1983-1994: a population-based study | 34 population-based cancer registries | ICD-9 | yes | 73022 | unreported | unreported |
| Gatta G, Lasota MB, Verdecchia A | 1998 | Survival of European women with gynaecological tumours, during the period 1978-1989 | population-based cancer registries in 17 countries | ICD-O-3/ICD-9 | yes | 25350 | 27735 | 29107 |
| Wenzel HHB, Bekkers RLM, Lemmens V,et al | 2021 | No improvement in survival of older women with cervical cancer-a nationwide study | Netherlands Cancer Registry | unreported | unreported | 21644 | unreported | unreported |
| Brenner H, Hakulinen T | 2001 | Long-term cancer patient survival achieved by the end of the 20th century: most up-to-date estimates from the nationwide Finnish cancer registry | Finnish Cancer Registry | unreported | yes | 4033 | 11617 | 10789 |
| Talbck M, Dickman PW | 2012 | Predicting the survival of cancer patients recently diagnosed in Sweden and an evaluation of predictions published in 2004 | Swedish National Cancer Registry (NCR)；. The Swedish Quality Registry for Gynecologic Cancer (SQRGC) | ICD-10 | yes | 2212 | unreported | unreported |
| Emmett M, Gildea C, Nordin A,et al | 2018 | Cervical cancer - does the morphological subtype affect survival rates? | National Cancer Data Repository (NCDR) | ICD-O-2/ICD-10 | yes | 12131 | unreported | unreported |
| Grundmann N, Meisinger C, Trepel M, et al | 2020 | Trends in cancer incidence and survival in the Augsburg study region-results from the Augsburg cancer registry | Augsburg cancer registry | ICD-10 | yes | 373 | 1022 | 703 |
| Brenner H, Stegmaier C, Ziegler H | 2005 | Long-term survival of cancer patients in Germany achieved by the beginning of the third millenium | the population-based Saarland Cancer Registry, | ICD-9 | yes | 1087 | 1874 | 1244 |
| Levi F, La Vecchia C, Randimbison L, Te VC | 1994 | Incidence, mortality and survival from invasive cervical cancer in Vaud, Switzerland, 1974-1991 | the population-based Vaud Cancer Registry | ICD-O/ICD-8 | yes | 695 | unreported | unreported |
| Houterman S, Janssen-Heijnen MLG, van de Poll-Franse LV, et al | 2006 | Higher long-term cancer survival rates in southeastern Netherlands using up-to-date period analysis | Eindhoven Cancer Registry | unreported | unreported | unreported | unreported | unreported |
| Minelli L, Stracci F, Prandini S, et al | 2004 | Gynaecological cancers in Umbria (Italy): trends of incidence, mortality and survival, 1978-1998 | population-based Cancer Registry of Umbria | ICD-9 | yes | 198 | 568 | 446 |
| Ojamaa K, Innos K, Baburin A, et al | 2018 | Trends in cervical cancer incidence and survival in Estonia from 1995 to 2014 | Estonian Cancer Registry | ICD-O-3 | yes | 3403 | unreported | unreported |
| Ulinskas K, Aleknaviciene B, Smailyte G | 2013 | Demographic differences in cervical cancer survival in Lithuania | Lithuanian Cancer Registry | ICD-10 | yes | 6680 | unreported | unreported |
| Bravo LE, García LS, Collazos PA | 2014 | Cancer survival in Cali, Colombia: a population-based study, 1995-2004 | Cancer Registry of Cali | ICD-10 | yes | 2469 | unreported | unreported |
| Hislop TG, Bajdik CD, Regier MD, et al | 2007 | Ethnic differences in survival for female cancers of the breast, cervix and colorectum in British Columbia, Canada | British Columbia cancer registry | ICD-O | yes | 3167 | unreported | unreported |
| Gari A, Lotocki R, Krepart G, et al | 2008 | Cervical cancer in the province of Manitoba: a 30-year experience | Manitoba Cancer Registry (MCR) | ICD-O/ICD-9 | unreported | 1927 | unreported | unreported |
| Jemal A, Ward EM, Johnson CJ, et al | 2017 | Annual report to the nation on the status of cancer, 1975-2014, featuring survival | the Centers for Disease Control and Prevention (CDC), the National Cancer Institute (NCI) | ICD-O/ICD-O-2/ICD-O-3/ICD-8/ICD-10 | yes | unreported | unreported | unreported |
| Gatta G, Capocaccia R, Coleman MP, et al | 2000 | Toward a comparison of survival in American and European cancer patients | SEER database | ICD-9 | yes | unreported | unreported | unreported |
| Taylor R, Bell J, Coates M, et al | 1996 | Cervical cancer in New South Wales women: Five-year survival, 1972 to 1991 | NSW Central Cancer Registry | unreported | unreported | 6992 | unreported | unreported |
| Yu XQ, O'Connell DL, Gibberd RW, et al | 2006 | Trends in survival and excess risk of death after diagnosis of cancer in 1980-1996 in New South Wales, Australia | NSW Central Cancer Registry | ICD-O-2 | yes | 5957 | 5793 | 5375 |
| Diaz A, Baade PD, Valery PC, et al | 2018 | Comorbidity and cervical cancer survival of Indigenous and non-Indigenous Australian women: A semi-national registry-based cohort study (2003-2012) | six Australian state-based cancer registries | ICD-10 | unreported | 4467 | unreported | unreported |
| Inoue S, Hosono S, Ito H, et al | 2018 | Improvement in 5-year relative survival in cancer of the corpus uteri from 1993-2000 to 2001-2006 in Japan | the population-based cancer registries of six prefectures (Yamagata, Miyagi, Fukui, Niigata, Osaka, and Nagasaki) | ICD-10/ICD-O-3 | yes | unreported | 8562 | unreported |
| Ioka A, Tsukuma H, Ajiki W, et al | 2005 | Influence of hospital procedure volume on uterine cancer survival in Osaka, Japan | Osaka Cancer Registry | ICD-10 | yes | 2035 | 499 | 61 |
| Yagi A, Ueda Y, Ikeda S, et al | 2022 | Improved long-term survival of corpus cancer in Japan: a 40-year population-based analysis | Osaka Cancer Registry | ICD-10/ICD-O-3 | unreported | unreported | 15225 | unreported |
| Ha HI, Chang HK, Park SJ, et al | 2021 | The incidence and survival of cervical, ovarian, and endometrial cancer in Korea, 1999-2017: Korea Central Cancer Registry | Korea Central Cancer Registry | unreported | unreported | unreported | unreported | unreported |
| Pavlík T, Májek O, Büchler T, et al | 2014 | Trends in stage-specific population-based survival of cancer patients in the Czech Republic in the period 2000-2008 | Czech National Cancer Registry | unreported | yes | 4870（2000-2004）3777（2005-2009） | 7392（2000-2004）6288（2005-2009） | 5190（2000-2004）3668（2005-2009） |
| Jensen KE, Hannibal CG, Nielsen A, et al | 2008 | Social inequality and incidence of and survival from cancer of the female genital organs in a population-based study in Denmark, 1994-2003 | nationwide registers | ICD-10 | unreported | 3007 | 3826 | 3855 |
| Ojamaa K, Veerus P, Baburin A, et al | 2019 | Increasing incidence and survival of corpus uteri cancer in Estonia over the past two decades | Estonian Cancer Registry | ICD-10 | yes | unreported | 4281 | unreported |
| Dickman PW, Hakulinen T, Luostarinen T, et al | 1999 | Survival of cancer patients in Finland 1955-1994 | Finnish Cancer Registry | ICD-7 | yes | 1464 | 5030 | 4126 |
| Boll D, Verhoeven RH, van der Aa MA, et al | 2012 | Incidence and survival trends of uncommon corpus uteri malignancies in the Netherlands, 1989-2008 | the nationwide population-based Netherlands Cancer Registry (NCR) | ICD-O-3 | unreported | unreported | 30960 | unreported |
| Ioka A, Tsukuma H, Ajiki W,et al | 2003 | Ovarian cancer incidence and survival by histologic type in Osaka, Japan | Osaka Cancer Registry’s data | ICD-10 | yes | unreported | unreported | 2431 |
| Chung HH, Hwang SY, Jung KW, et al | 2007 | Ovarian cancer incidence and survival in Korea: 1993-2002 | Korea Central Cancer Registry and the Gynecologic Oncology Committee of Korean Society of Obstetrics and Gynecology | ICD-O | yes | unreported | unreported | 11404 |
| Shin D, Jung K, Bae J | 2020 | Conditional relative survival of ovarian cancer: a Korean national cancer registry study | Korean National Cancer Registry Study | ICD-O-3 | unreported | unreported | unreported | 25859 |
| Ries LA | 1993 | Ovarian cancer. Survival and treatment differences by age. | SEER database | unreported | yes | unreported | unreported | 20772 |
| Cabasag CJ, Butler J, Arnold M, et al | 2020 | Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2): a population-based study | 21 population-based cancer registries included Australia (New South Wales (NSW), Victoria, and Western Australia), Canada (Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland, Nova Scotia, Ontario, Prince Edward Island, Quebec, and Saskatchewan), Denmark,Ireland, New Zealand, Norway, and the United Kingdom (UK) (England,Northern Ireland, Scotland, and Wales) | ICD-10/ICD-O-3 | yes | unreported | unreported | 58161 |
| Lambert P, Galloway K, Altman A, et al | 2017 | Ovarian cancer in Manitoba: trends in incidence and survival, 1992–2011 | Manitoba Cancer Registry. | ICD-10 | yes | unreported | unreported | 1931 |
| Karim-Kos HE, de Vries E, Soerjomataram I, et al | 2008 | Recent trends of cancer in Europe: A combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s | 21 European cancer registries, Denmark, Finland, Norway, Sweden, Ire\_x005f land, and the United Kingdom，Austria,France, Germany, The Netherlands, and Switzerland，Croatia, Italy, Malta, Slovenia, and Spain，Czech Republic, Lithuania, and Poland | ICD-10 | yes | unreported | unreported | unreported |
| Hamidou Z, Causeret S, Dabakuyo TS, et al | 2010 | Population-based study of ovarian cancer in Cote d'Or: prognostic factors and trends in relative survival rates over the last 20 years | Côte d’Or gynaecologic cancer registry | unreported | yes | unreported | unreported | 748 |
| Karim-Kos HE, Kiemeney LALM, Louwman MWJ, et al | 2012 | Progress against cancer in the Netherlands since the late 1980s: An epidemiological evaluation | the population-based Netherlands Cancer Registry (NCR) | ICD-10 | unreported | unreported | unreported | unreported |
| Balvert-Locht HR, Coebergh JW, Hop WC, et al | 1991 | Improved prognosis of ovarian cancer in The Netherlands during the period 1975-1985: a registry-based study | Eindhoven cancer registry：a population-based registry in the Southeast Netherlands | unreported | unreported | unreported | unreported | 568 |
| Jun J, Zhang Y, Chen Y, et al | 2011 | Analysis of survival rate of cervical cancer patients during 2001-2007 in Qidong City | Qidong City Center for Disease Control and Prevention | ICD-O-2 | unreported | 241 | unreported | unreported |
| Chen J, R S, Shen Z, et al | 1998 | Population-based cancer survival: an analysis of 16922 cases | Qidong City Center for Disease Control and Prevention | ICD-9 | yes | 200 | unreported | unreported |
| Lu H, Li L, Cheng Y, et al | 2022 | Timely estimates of 5-year relative survival for patients with cervical cancer: a period analysis using cancer registry data from Taizhou, Eastern China | four cancer registries with high-quality data from Taizhou, eastern China | ICD-10 | yes | 4314 | unreported | unreported |
| Ioka A, Ito Y, Tsukuma H | 2007 | Factors relating to poor survival rates of aged cervical cancer patients: a population-based study with the relative survival model in Osaka, Japan | Osaka Cancer Registry | ICD-10 | unreported | 10048 | unreported | unreported |
| Shin DW, Jung KW, Ha J, Bae J | 2022 | Conditional relative survival of patients with endometrial cancer: a Korean National Cancer Registry study | Korean National Cancer Registry | ICD-O-3 | unreported | unreported | 22131 | unreported |
| Vernooij F, Heintz APM, Witteveen PO,et al | 2008 | Specialized care and survival of ovarian cancer patients in the Netherlands: nationwide cohort study | Netherlands Cancer Registry | ICD-10/ICD-O-2/3 | yes | unreported | unreported | 8621 |
| De Rijke JM, Schouten LJ, Volovics A, et al | 1998 | Age-specific differences in treatment and survival of ovarian cancer patients in the province of Limburg, the Netherlands, 1986-92 | the population-based Maastricht Cancer Registry（covers the regions of Middle and South Lim burg） | unreported | yes | unreported | unreported | 367 |
| Stewart SL, Harewood R, Matz M, et al | 2017 | Disparities in ovarian cancer survival in the United States (2001-2009): findings from the CONCORD-2 study | 37 NPCR or SEER state-wide cancer registries | ICD-O-3 | unreported | unreported | unreported | 172849 |
| Yoshida Y, Schmaltz CL, Jackson-Thompson J,et al | 2018 | Ovarian Cancer Survival in Missouri, 1996-2014 | Missouri Cancer Registry | ICD-O-3 | unreported | unreported | unreported | 7046 |
| Bjorge T, Thoresen SO, Skare GB | 1993 | Incidence, survival and mortality in cervical cancer in Norway, 1956-1990 | Norwegian Cancer Registry | ICD-7 | unreported | unreported | unreported | 2687 |
| Wong KH, Mang OWK, Au KH, et al | 2012 | Incidence, mortality, and survival trends of ovarian cancer in Hong Kong, 1997 to 2006: a population-based study | the Hong Kong Cancer Registry (HKCaR) | ICD-9/10/ICD-O | yes | unreported | unreported | 2941 |
| van Altena AM, Karim-Kos HE, de Vries E, et al | 2012 | Trends in therapy and survival of advanced stage epithelial ovarian cancer patients in the Netherlands | Netherlands Cancer Registry | ICD-O-3 | yes | unreported | unreported | 23399 |
| Bennetsen AKK, Baandrup L, Aalborg GL, et al | 2020 | Non-epithelial ovarian cancer in Denmark - Incidence and survival over nearly 40 years | Danish Cancer Registry | ICD-O-3 | yes | unreported | unreported | 720 |
| Wei K, Liang Z, Cen H | 2016 | Net survival of cancers in Zhongshan city,Guangdong province,1995－2009 | Zhongshan City Cancer Registry | ICD-O-3 | unreported | 498 | unreported | 376 |
| Wei K, Liang Z, Li Z | 2020 | Net survival of major cancers in Zhongshan city of Guangdong province from 2003 to 2013 | Zhongshan City Cancer Registry | ICD-O-3 | unreported | 802 | unreported | 502 |
| Allemani C, Matsuda T, Di Carlo V, et al | 2018 | Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries | 322 population-based cancer registries in 71 countries and territories | ICD-O-3 | yes | 527624 | unreported | 238719 |
| Allemani C, Weir HK, Carreira H, et al | 2015 | Global surveillance of cancer survival 1995-2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2) | 279 population-based cancer registries in 67 countries | ICD-O-3 | yes | 602225 | unreported | 779302 |
| Lim GH, Wong CS, Chow KY,et al | 2009 | Trends in long-term cancer survival in Singapore: 1968-2002 | Singapore Cancer Registry | unreported | yes | unreported | unreported | unreported |
| Zeng H, Chen W, Zheng R, et al | 2018 | Changing cancer survival in China during 2003–15: a pooled analysis of 17 population-based cancer registries | 17 cancer registries in China | ICD-10,ICD-O-3 | unreported | 11496 | 11531 | 8576 |
| Quaresma M, Coleman MP, Rachet B | 2015 | 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971-2011: A population-based study | the National Cancer Registry and the Welsh Cancer Intelligence and Surveillance Unit | ICD-10 | unreported | 125676 | 171375 | 183451 |
| Sant M, Lopez MDC, Agresti R, et al | 2015 | Survival of women with cancers of breast and genital organs in Europe 1999-2007: Results of the EUROCARE-5 study | over 80 population-based cancer registries in 29 countries grouped into five European regions | ICD-O-3 | unreported | 104696 | 199046 | 157393 |
| Antunes L, Roche L, José Bento M | 2017 | Trends in net survival from corpus uteri cancer in six European Latin countries: results from the SUDCAN population-based study | the EUROCARE database for six European Latin countries: Belgium, France, Italy, Portugal, Spain and Switzerland | ICD-O-3 | unreported | unreported | 25508 | unreported |
| Antunes L, Santos LL, Bento MJ | 2017 | Survival from cancer in the north region of Portugal: results from the first decade of the millennium | he North Region Cancer Registry of Portugal database（RORENO database） | ICD-O-3,ICD-10 | unreported | 2254 | 2364 | 1184 |
| Chen TH, Jansen L, Gondos A, et al | 2012 | Survival of endometrial cancer patients in Germany in the early 21st century: A period analysis by age, histology, and stage | a pooled German national dataset including data from 11 cancer registries | ICD-10,ICD-O-3 | unreported | unreported | unreported | unreported |
| Jansen L, Castro FA, Gondos A, et al | 2015 | Recent cancer survival in Germany: an analysis of common and less common cancers | 11 population-based cancer registries covering 13 of 16 German federal states | ICD-10 | yes | 222005 | 43610 | 30196 |
| Cowppli-Bony A, Uhry Z, Remontet L, et al | 2017 | Survival of solid cancer patients in France, 1989-2013: A population-based study | 19 population-based cancer registries in the FRANCIM common database | ICD-O-3 | unreported | 2938 | 6582 | 4702 |
| Innos K, Baburin A, Aareleid T | 2014 | Cancer patient survival in Estonia 1995-2009: Time trends and data quality | the Estonian Cancer Registry | ICD-10 | yes | 2335 | 2681 | 2207 |
| Arnold M, Rutherford MJ, Bardot A, et al | 2019 | Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study | population-based cancer registries in 21 jurisdictions in seven countries (Australia, Canada, Denmark, Ireland, New Zealand, Norway, and the UK) | ICD-10 | unreported | unreported | unreported | 215017 |
| Caetano dos Santos FL, Wojciechowska U, Michalek IM, et al | 2022 | Progress in cancer survival across last two decades: a nationwide study of over 1.2 million Polish patients diagnosed with the most common cancers | the Polish Cancer Registry (PLCR) | ICD-10 | unreported | 58056 | unreported | 64330 |
| Ojamaa K, Veerus P, Baburin A, et al | 2017 | Time trends in ovarian cancer survival in Estonia by age and stage | Estonian Cancer Registry(ECR) | ICD-O-3 | yes | unreported | unreported | 2296 |
| Francis Okongo,David Martin Ogwang, Biying Liu, et al | 2019 | Cancer incidence in Northern Uganda (2013–2016) | Gulu Cancer Registry | ICD-O-3 | unreported | 486 | 7 | 19 |
| Bo Nilsson, Evi Gustavson-Kadaka, Timo Hakulinen, et al | 1997 | Cancer survival in Estonian migrants to Sweden | National Swedish Cancer Registry (NCR) | unreported | yes | unreported | unreported | 6008 |
| Freddie Bray BSc,Jacques Ferlay ME,Isabelle Soerjomataram MD,et al | 2018 | Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries | LOBOCAN 2018 database | ICD-10 | unreported | unreported | unreported | unreported |
| Gultekin M,Zayifoglu Karaca M,MDundar S. | 2015 | Gynecological cancer trends and 5-year survival in turkey: Analysis of 13.590 cancer patients | 9 nationwide cancer registry centers | unreported | unreported | 2745 | 6020 | 4240 |
| Magdalena Bielska-Lasota, Silvia Rossi, Michalina Krzyżak et al | 2020 | Reasons for low cervical cancer survival in new accession European Union countries: a EUROCARE-5 study | EUROCARE-5 database | ICD-O-3 | unreported | 101714 | unreported | unreported |
| F Levi 1, L Randimbison, V C Te, S Franceschi, C La Vecchia | 1992 | Trend in cancer survival in Vaud, Switzerland | Vaud Cancer Registry | ICD-O | yes | 194 | 313 | 210 |
| A. Gondos,B. Holleczek,V. Arndt, et al | 2007 | Trends in population-based cancer survival in Germany: to what extent does progress reach older patients? | Saarland Cancer Registry | ICD-9 | yes | unreported | 3530 | 2260 |

# ***Note***:-, No report or nonavailable in the original article.

# **Supplementary Table S3**: Age-specific 5-year relative/net survival rates (%) of cervical cancer in selected countries and regions during 1980-2018

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Continent** | **County** | **Region** | **Period** | **＜44** | **45-54** | **55-64** | **65-74** | **75+** |
| Asia | China | Qidong, Jiangsu1+, 2 | 1982-1991 | - | 43.8 | 41.7 | 28.0 | 6.9 |
|  |  |  | 2001-2007 | - | 64.5 | 41.3 | 18.4 | 36.4 |
|  |  | Zhejiang3 | 2005-2010 | 83.8 | 76.7 | 67.5 | 56.3 | 42.1 |
|  |  | Taizhou, Zhejiang4 | 2014-2018 | 95.6 | 93.3 | 89.6 | 83.2 | 68.7 |
|  | India | Mumbai5+ | 1992-1994 | - | 49.4 | 26.3 | 20.8 | 48.0 |
|  | Japan | Osaka6+ | 1980-1984 | - | - | 68.7 | 52.8 | |
|  |  |  | 1985-1989 | - | - | 72.6 | 52.3 | |
|  |  |  | 1990-1994 | - | - | 69.4 | 56.4 | |
|  |  |  | 1995-1999 | - | - | 63.6 | 53.3 | |
| Europe7-9 |  |  | 1981-1983 | 73.0 | 63.0 | 62.0 | 48.0 | 29.0 |
|  |  |  | 1984-1986 | 79.0 | 57.0 | 63.0 | 52.0 | 33.0 |
|  |  |  | 1987-1989 | 76.0 | 64.0 | 58.0 | 55.0 | 43.0 |
|  |  |  | 1989-1991 | 79.0 | 69.0 | 61.0 | 50.0 | 35.0 |
|  |  |  | 1992-1994 | 79.0 | 68.0 | 59.0 | 48.0 | 31.0 |
|  |  |  | 1995-1999 | 80.4 | 68.2 | 60.9 | 52.5 | 36.9 |
|  | Denmark8 |  | 1983-1994 | 83.0 | 68.0 | 58.0 | 55.0 | 29.0 |
|  | Finland8 |  | 1983-1994 | 80.0 | 66.0 | 61.0 | 48.0 | 37.0 |
|  | Iceland8 |  | 1983-1994 | 87.0 | 76.0 | 74.0 | 67.0 | 34.0 |
|  | Norway8 |  | 1983-1994 | 82.0 | 70.0 | 64.0 | 55.0 | 39.0 |
|  | Sweden8 |  | 1983-1994 | 85.0 | 74.0 | 60.0 | 52.0 | 41.0 |
|  | France8 |  | 1983-1994 | 81.0 | 70.0 | 67.0 | 60.0 | 38.0 |
|  | Germany8 |  | 1983-1994 | 76.0 | 57.0 | 65.0 | 60.0 | 38.0 |
|  | England8 |  | 1983-1994 | 78.0 | 65.0 | 58.0 | 47.0 | 31.0 |
|  | Scotland8 |  | 1983-1994 | 76.0 | 64.0 | 53.0 | 42.0 | 23.0 |
|  | Wales8 |  | 1983-1994 | 74.0 | 61.0 | 54.0 | 44.0 | 42.0 |
|  | Italy8 |  | 1983-1994 | 75.0 | 68.0 | 68.0 | 51.0 | 30.0 |
|  | Spain8 |  | 1983-1994 | 79.0 | 72.0 | 68.0 | 47.0 | 47.0 |
|  | Estonia8 |  | 1983-1994 | 60.0 | 57.0 | 58.0 | 56.0 | 29.0 |
|  | Poland8 |  | 1983-1994 | 65.0 | 55.0 | 44.0 | 37.0 | 20.0 |
|  | Slovakia8 |  | 1983-1994 | 71.0 | 66.0 | 55.0 | 44.0 | 28.0 |
|  | Slovenia8 |  | 1983-1994 | 76.0 | 61.0 | 53.0 | 48.0 | 27.0 |
|  | Netherlands8, 10\*+ |  | 1983-1994 | 79.0 | 65.0 | 68.0 | 64.0 | 56.0 |
|  |  |  | 1994-1998 | 85.0 | 68.0 | 66.0 | 50.0 | 36.0 |
|  |  |  | 1999-2003 | 84.0 | 73.0 | 62.0 | 55.0 | 34.0 |
|  |  |  | 2004-2008 | 86.0 | 74.0 | 62.0 | 51.0 | 40.0 |
|  |  |  | 2009-2013 | 88.0 | 78.0 | 67.0 | 51.0 | 35.0 |
|  |  |  | 2014-2018 | 88.0 | 77.0 | 70.0 | 54.0 | 34.0 |
|  |  |  | 1989-2018 | 86.0 | 73.0 | 64.0 | 52.0 | 36.0 |
|  | Switzerland8 |  | 1983-1994 | 78.0 | 70.0 | 64.0 | 51.0 | 39.0 |
|  |  | Vaud11 | 1980-1982 | 69.0 | | 56.0 | 50.0 | |
|  |  |  | 1983-1985 | 72.0 | | 58.0 | 50.0 | |
|  |  |  | 1986-1988 | 76.0 | | 77.0 | 49.0 | |

***Note***:-, No report or nonavailable in the original article. \* indicates statistically significant differences at different times in the original article. + indicates statistically significant differences between different groups (different ages) in the original article

# **Supplementary Table S4:** Age-specific 5-year relative/net survival rates (%) of uterine corpus cancer in selected countries and regions during 1981-2016

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Continent** | **County** | **Region** | **Period** | **＜44** | **45-54** | **55-64** | **65-74** | **75+** |
| Europe7,9 |  |  | 1981-1983 | 92.0 | 82.0 | 78.0 | 69.0 | 54.0 |
|  |  |  | 1984-1986 | 88.0 | 88.0 | 78.0 | 69.0 | 64.0 |
|  |  |  | 1987-1989 | 87.0 | 85.0 | 80.0 | 71.0 | 56.0 |
|  |  |  | 1995-1999 | 86.3 | 88.9 | 85.3 | 75.3 | 62.4 |
|  | Germany | Saarland12 | 1999-2003 | 80.7 | | 88.6 | 72.9 | 72.7 |
|  | Estonia13 |  | 1996-2002 | 89.0 | | 81.0 | 66.0 | 56.0 |
|  |  |  | 2003-2009 | 89.0 | | 78.0 | 72.0 | 52.0 |
|  |  |  | 2010-2016 | 95.0 | | 84.0 | 76.0 | 66.0 |
|  | France14 |  | 1992-1995 | - | - | 84.0 | 76.0 | 63.0 |
|  |  |  | 1996-1999 | - | - | 85.0 | 77.0 | 65.0 |
|  |  |  | 2000-2003 | - | - | 86.0 | 79.0 | 67.0 |
|  |  |  | 2004-2007 | - | - | 86.0 | 80.0 | 69.0 |
|  | Italy14 |  | 1992-1996 | - | - | 86.0 | 79.0 | 68.0 |
|  |  |  | 1996-2000 | - | - | 87.0 | 81.0 | 70.0 |
|  |  |  | 2000-2004 | - | - | 88.0 | 82.0 | 72.0 |
|  |  |  | 2004-2008 | - | - | 89.0 | 83.0 | 74.0 |
|  | Spain14 |  | 1992-1997 | - | - | 81.0 | 73.0 | 61.0 |
|  |  |  | 1996-2001 | - | - | 83.0 | 76.0 | 64.0 |
|  |  |  | 2000-2005 | - | - | 85.0 | 78.0 | 67.0 |
|  |  |  | 2004-2009 | - | - | 86.0 | 80.0 | 70.0 |
|  | Switzerland14 |  | 1992-1998 | - | - | 88.0 | 81.0 | 69.0 |
|  |  |  | 1996-2002 | - | - | 88.0 | 81.0 | 71.0 |
|  |  |  | 2000-2006 | - | - | 87.0 | 81.0 | 73.0 |
|  |  |  | 2004-2010 | - | - | 87.0 | 82.0 | 75.0 |
|  | Belgium14 |  | 2000-2007 | - | - | 89.0 | 82.0 | 71.0 |
|  |  |  | 2004-2011 | - | - | 88.0 | 83.0 | 75.0 |
|  | Portugal14 |  | 2000-2008 | - | - | 80.0 | 72.0 | 62.0 |
|  |  |  | 2004-2012 | - | - | 83.0 | 77.0 | 67.0 |

***Note:***-, No report or nonavailable in the original article.

# **Supplementary Table S5:** Age-specific 5-year relative/net survival rates (%) of ovarian cancer in selected countries and regions during 1981-2010

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **County** | **Region** | **Period** | **＜44** | **45-54** | **55-64** | **65-74** | **75+** |
| China | Zhejiang3 | 2005-2010 | 74.3 | 54.2 | 45.9 | 44.2 | 41.8 |
| India | Mumbai5+ | 1990-1994 | - | 28.1 | 13.8 | 5.7 | 12.7 |
| Germany | Saarland11,15 | 1981-1985 | 41.7 | | 36.7 | 21.1 | |
|  |  | 1986-1990 | 54.8 | | 30.8 | 24.0 | |
|  |  | 1991-1995 | 60.1 | | 42.9 | 26.5 | |
|  |  | 1999-2003 | 72.1 | | 49.1 | 37.2 | 21.7 |
| United States16 |  | 1981-1987 | 67.3 | 45.9 | 36.3 | 26.5 | 18.7 |
| Europe8,17 |  | 1981-1983 | 61.0 | 38.0 | 32.0 | 21.0 | 22.0 |
|  |  | 1984-1986 | 70.0 | 46.0 | 34.0 | 22.0 | 18.0 |
|  |  | 1987-1989 | 64.0 | 44.0 | 34.0 | 20.0 | 18.0 |
|  |  | 1995-1999 | 71.3 | 54.7 | 42.2 | 32.0 | 20.7 |
|  |  | 2000-2007 | 70.9 | 56.1 | 44.5 | 33.9 | 20.1 |
| Europe(Northern)18 |  | 2000-2007 | 73.7 | 57.8 | 48.0 | 39.1 | 22.9 |
| Europe(Central)18 |  | 2000-2007 | 71.8 | 58.6 | 47.5 | 37.7 | 22.7 |
| Europe(Southern)18 |  | 2000-2007 | 73.4 | 58.1 | 47.1 | 33.7 | 18.1 |
| Europe(Eastern)18 |  | 2000-2007 | 66.4 | 51.4 | 41.6 | 29.0 | 19.4 |
|  | UK and Ireland18 | 2000-2007 | 68.9 | 47.8 | 36.8 | 26.8 | 14.5 |
|  | France19 | 1989-2010 | 74.0 | 57.0 | 46.0 | 35.0 | 23.0 |

***Note***:-, No report or nonavailable in the original article. + indicates statistically significant differences between different groups (different ages) in the original article.

# **Supplementary Table S6-1**: Stage-specific 5-year relative/net survival rates (%) of cervical cancer in selected countries and regions during 1983-2019#

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Continent | Country | Region | Period | Localized | Regional | Distant | Unknown |
| Asia | Korea20,21 |  | 1996-2015 | 91.9 | 72.3 | 27.0 | 73.9 |
|  |  |  | 2015-2019 | 94.6 | 73.1 | 27.8 | - |
|  | Japan | Osaka22\* | 1987-1994 | 83.4 | 45.5 | 5.1 | - |
|  |  |  | 1995-2002 | 84.5 | 47.8 | 3.5 | - |
|  |  |  | 2003-2010 | 90.4 | 59.6 | 6.9 | - |
|  | Japan d23\* |  | 1993-1996 | 93.6 | 52.8 | 9.8 | - |
|  |  |  | 1997-1999 | 92.3 | 53.1 | 12.8 | - |
|  | Thailand e24 |  | 1997-2001 | 94.6 | 81.6 | 45.3 | 85.5 |
|  |  |  | 2002-2006 | 95 | 79.2 | 50.2 | 83.1 |
|  |  |  | 2008-2012 | 96.4 | 81.8 | 30.9 | 76 |
|  | Kuwait25 |  | 2000-2004 | 54.4 | 59.3 | - | 80.4 |
|  |  |  | 2005-2009 | 88.4 | 68.3 | - | 72.9 |
|  |  |  | 2010-2013 | - | 94.7 | - | 62.2 |
|  | India | Mumbai5+ | 1992-1994 | 66.3 | 41.4 | 3.6 | 33.5 |
|  | Turkey26+ |  | 2009 | 80.0 | 50.0 | 22.0 | 57.0 |
| Europe27 |  |  | 2000-2007 | 81.2 | 45.8 | 15.7 | 61.2 |
|  | Denmark8 |  | 1983-1994 | 83 | 51 | 25 | - |
|  | Finland8 |  | 1983-1994 | 84 | 52 | 27 | - |
|  | Norway8 |  | 1983-1994 | 85 | 58 | 22 | - |
|  | Germany | Saarland8 | 1983-1994 | 84 | 45 | 16 | - |
|  | Switzerland | Basel8 | 1983-1994 | 72 | 30 | 0 | - |
|  |  | Geneva8 | 1983-1994 | 83 | 59 | 23 | - |
|  | UK | East Anglia8 | 1983-1994 | 88 | 55 | 23 | - |
|  |  | Thames8 | 1983-1994 | 71 | 48 | 16 | - |
|  |  | West Midlands8 | 1983-1994 | 83 | 33 | 13 | - |
|  |  | Yorkshire8 | 1983-1994 | 79 | 52 | 26 | - |
|  | Italy | Tuscany8 | 1983-1994 | 78 | 59 | 19 | - |
|  |  | Varese8 | 1983-1994 | 78 | 48 | 3 | - |
|  | Estonia8 |  | 1983-1994 | 85 | 50 | 11 | - |
|  | Poland | Krakow8 | 1983-1994 | 57 | 38 | 15 | - |
|  | Slovakia8 |  | 1983-1994 | 78 | 19 | 12 | - |
|  | Slovenia8 |  | 1983-1994 | 82 | 43 | 12 | - |
|  |  |  | 1987-1991 | 82.0 | 49.0 | 21.0 | 66.0 |
| America | United States28 |  | 2013-2019 | 91.2 | 59.8 | 18.9 | 61.8 |

***Note:***\* indicates statistically significant differences at different times in the original article.

+ indicates statistically significant differences between different groups (different stages) in the original article.

d Sixregistries (Miyagi, Yamagata, Niigata, Fukui, Osaka and Nagasaki) with high quality were included in the original article.

e Five Thai provinces (Bangkok, Chiang Mai, Khon Kaen, Lampang, and Songkhla) were included in the original article.

-, No report or nonavailable in the original article.

#Stage categories: localized, regional, distant and unknown.

# **Supplementary Table S6-2:** Stage-specific 5-year relative/net survival rates (%) of cervical cancer in selected countries and regions during 1983-2019 #

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Continent** | **Country** | **Region** | **Period** | **Ⅰ** | **Ⅱ** | **Ⅲ** | **Ⅳ** | **Unknown** |
| Asia | China | Hong Kong29+ | 1997-2006 | 90.9 | 71.0 | 41.7 | 7.8 | 63.6 |
|  |  | Taiwan30 | 2004-2008 | 93.1 | 73.5 | 58.7 | 22.0 | - |
|  | Korea31+ |  | 1993-2002 | 94.2 | 69.7 | 38.9 | 21.1 | - |
| Europe | Estonia32 |  | 2005-2009 | 96.0 | 72.0 | 52.0 | 24.0 | 49.0 |
|  |  |  | 2010-2014 | 98.0 | 74.0 | 57.0 | 22.0 | 43.0 |
|  | Czech33 |  | 2000-2004 | 89.1 | 60.8\* | 43.7 | 10.0 | - |
|  |  |  | 2005-2008 | 89.5 | 66.0\* | 46.9 | 11.4 | - |
|  | Lithuanian34 |  | 1990-1994 | 86.6 | 58.3 | 23.1 | 1.6 | 40.9 |
|  |  |  | 1995-1999 | 87.0 | 64.0 | 34.4 | 5.6 | 53.0 |
|  |  |  | 2000-2004 | 89.9 | 61.9 | 35.1 | 4.4 | 53.4 |

***Note***:#Stage categories: clinical stages of I, II, III, IV, and unknown.

-, No report or nonavailable in the original article.

\* indicates statistically significant differences at different times in the original article.

+ indicates statistically significant differences between different groups (different stages) in the original article.

# **Supplementary Table S7-1**: Stage-specific 5-year relative/net survival rates (%) of uterine corpus cancer in selected countries and regions during 1993-2019 #

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Country** | **Period** | **Localized** | **Regional** | **Distant** | **Unknown** |
| Korea20, 35 | 1997-2016 | 96.6 | 80.9 | 34.5 | 85.5 |
|  | 2015-2019 | 96.6 | 82.2 | 31.7 | - |
| Turkey26+ | 2009 | 92.0 | 66.0 | 38.0 | 87.0 |
| Japan d23, 36 | 1993-1996 | 92.9 | 63.4\* | 22.7 | - |
|  | 1997-1999 | 92.4 | 53.7\* | 17.2 | - |
|  | 2001-2006 | 95.0\* | 63.8\* | 22.6\* | - |
| Osaka,Japan37 | 2001-2012 | 94.2 | 64.4 | 19.1 | - |
| United States28 | 2013-2019 | 94.9 | 69.8 | 18.4 | 57.6 |
| Finland38 | 1985-1994 | 92.0 | 51.0 | 37.0 | - |

***Note***:d Sixregistries (Miyagi, Yamagata, Niigata, Fukui, Osaka and Nagasaki) with high quality were included in the original article.

-, No report or nonavailable in the original article.

\* indicates statistically significant differences at different times in the original article.

+ indicates statistically significant differences between different groups (different stages) in the original article

#Stage categories: localized, regional, distant and unknown

# **Supplementary Table S7-2:** Stage-specific 5-year relative/net survival rates (%) of uterine corpus cancer in selected countries and regions during 1993-2019 #

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Country** | **Period** | **Ⅰ** | **Ⅱ** | **Ⅲ** | **Ⅳ** | **Unknown** |
| Czech33 | 2000-2004 | 88.8 | 72.1 | 47.0 | 18.8\* | - |
|  | 2005-2008 | 91.5 | 73.5 | 50.1 | 19.4\* | - |

***Note:***-, No report or nonavailable in the original article.

#Stage categories: clinical stages of I, II, III, IV, and unknown.

\* indicates statistically significant differences at different times in the original article.

# **Supplementary Table S8-1**: Stage-specific 5-year relative/net survival rates (%) of ovarian cancer in selected countries and regions during 1981-2019#

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Country** | **Region** | **Period** | **Localized** | **Regional** | **Distant** | **Unknown** |
| Korea44+ |  | 1997-2016 | 90.7 | 74.7 | 41.7 | 56.6 |
| Japanb23 |  | 1993-1996 | 89.6 | 40.5 | 15.4 | - |
|  |  | 1997-1999 | 86.0 | 43.5 | 20.3 | - |
| India | Mumbai5+ | 1992-1994 | 54.7 | 20.4 | 4.6 | 21.8 |
| Turkey26 |  | 2009 | 77.0 | 57.0 | 29.0 | 50.0 |
| Kuwait25 |  | 2000-2004 | 100.0 | 36.0 | 6.4 | - |
|  |  | 2005-2009 | 81.1 | 54.2 | 23.1 | 43.4 |
|  |  | 2010-2013 | - | 61.6 | 0.1 | 60.6 |
| Finland38 |  | 1985-1994 | 84.0 | 48.0 | 18.0 | - |
| United States28, 45 |  | 2001-2003 | 84.8 | 53.9 | 25.2 | 33.1 |
|  |  | 2004-2009 | 86.4 | 60.9 | 27.4 | 32.6 |
|  |  | 2013-2019 | 92.4 | 72.9 | 31.5 | 36.4 |
|  | Missouri46 | 1996-2014 | 92.7 | 35.9 | | 19.4 |

***Note***:-, No report or nonavailable in the original article.

#Stage categories: localized, regional, distant and unknown.

+ indicates statistically significant differences between different groups (different stages) in the original article.

# **Supplementary Table S8-2:** Stage-specific 5-year relative/net survival rates (%) of ovarian cancer in selected countries and regions during 1981-2019#

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Country** | **Region** | **Period** | **Ⅰ** | **Ⅱ** | **Ⅲ** | **Ⅳ** | **Unknown** |
| Netherlands39 |  | 1996-2003 | 81.2 | 60.0 | 24.5 | 11.7 | - |
|  | Maastricht40 | 1986-1992 | 73.0 | | 20.0 | | - |
| French41+ |  | 1982-2005 | 85.0 | 48.0 | 29.0 | 14.0 | - |
| Czech33+ |  | 2000-2004 | 87.2 | 50.3\* | 29.1 | 14.2 | - |
|  |  | 2005-2008 | 87.6 | 52.0\* | 32.7 | 13.4 | - |
| Estonia42 |  | 1995-1999 | 82.0 | 48.0 | 25.0 | 11.0 | 41.0 |
|  |  | 2000-2004 | 87.0 | 72.0 | 26.0 | 8.0 | 47.0 |
|  |  | 2005-2009 | 91.0 | 67.0 | 35.0 | 16.0 | 18.0 |
| Sweden43 |  | 2009-2013 | 79.0 | 72.0 | 33.0 | 20.0 | - |
| United States16 |  | 1981-1987 | 83.9 | | 20.7 | | 21.6 |

***Note***: -, No report or nonavailable in the original article.

#Stage categories: clinical stages of I, II, III, IV, and unknown.

\* indicates statistically significant differences at different times in the original article.

+ indicates statistically significant differences between different groups (different stages) in the original article.

# **Supplementary Table S9:** Pathology-specific 5-year relative/net survival rates (%) of cervical cancer in selected countries and regions during 1980-2018

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Continent** | **Country** | **Region** | **Period** | **SCC(Squamous Cell Carcinoma)** | **ADC(Adenocarcinoma)** | **ASC(Adenosquamous Carcinoma)** | **Other** | **Unknown** |
| Asia | China | Hong Kong29+ | 1997-2006 | 72.6 | 70.5 | - | 60.0 | - |
|  | Korea21, 31+ |  | 1993-2002 | 78.9 | 74.4 | 77.3 | - | - |
|  |  |  | 1996-2015 | 82.6 | 78.5 | 79.2 | 60.0 | 63.7 |
|  | Turkey26 |  | 2009 | 64.0 | 56.0 | - | - | - |
| Europe | Sweden47 |  | 2011-2015 | 75.7 | 79.6 | 72.0 | 33.8 | - |
|  | England48 |  | 2006-2008 | 64.6 | 65.3 | 55.0 | 51.8 | - |
|  | Estonia32+\* |  | 1995-1999 | 61.0 | 55.0 | - | - | 42.0 |
|  |  |  | 2000-2004 | 65.0 | 66.0 | - | - | 33.0 |
|  |  |  | 2005-2009 | 72.0 | 65.0 | - | - | 38.0 |
|  |  |  | 2010-2014 | 71.0 | 63.0 | - | - | 30.0 |
|  | Netherlands9+\* |  | 1989-1993 | 67.0 | 65.0 | 60.0 | 48.0 | 89.0 |
|  |  |  | 1994-1998 | 70.0 | 67.0 | 67.0 | 39.0 | 69.0 |
|  |  |  | 1999-2003 | 71.0 | 70.0 | 61.0 | 40.0 | 64.0 |
|  |  |  | 2004-2008 | 72.0 | 74.0 | 76.0 | 32.0 | 68.0 |
|  |  |  | 2009-2013 | 75.0 | 72.0 | 73.0 | 45.0 | 39.0 |
|  |  |  | 2014-2018 | 76.0 | 74.0 | 82.0 | 38.0 | 23.0 |
|  |  |  | 1989-2018 | 72.0 | 71.0 | 70.0 | 40.0 | 70.0 |
|  | Canada | Manitoba49 | 1985-1999 | 68.0 | 65.0 | - | - | - |
|  | Switzerland | Vaud10 | 1980-1985 | 62.0 | 45.0 | - | 41.0 | - |
|  |  |  | 1986-1991 | 68.0 | 75.0 | - | 40.0 | - |
|  | Norway50 |  | 1981-1985 | 69.8 | 68.1 | - | - | - |

***Note***:-, No report or nonavailable in the original article. \* indicates statistically significant differences at different times in the original article.

+ indicates statistically significant differences between different groups (different pathology) in the original article

**Supplementary Table S10:** Pathology-specific 5-year relative/net survival rates (%) of endometrial cancer in selected countries and regions during 1989-2016

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Country** | **Period** | **Endometrial adenocarcinoma** | **Mucinous adenocarcinoma** | **Serous carcinoma** | **Sarcomas** | **Carcinosarcoma** | **Clear cell carcinoma** | **Others** |
| Korea35 | 1997-2016 | 93.2 | 90.9 | 60.5 | - | 51.5 | 74.8 | 72.6 |
| Japan36\* | 1993-2000 | 84.5 | - | - | - | 41.7 | - | 67.6 |
|  | 2001-2006 | 89.7 | - | - | - | 40.9 | - | 58.4 |
| Turkey26+ | 2009 | 91.0 | - | - | - | - | - | 73.0 |
| Netherlands51 | 1989-1993 | 82.0 | 77.0 | 73 | 47.0 | 34 | 55 | - |
|  | 1994-1998 | 84.0 | 89.0 | 71 | 53.0 | 32 | 56 | - |
|  | 1999-2003 | 86.0 | 84.0 | 56 | 46.0 | 35 | 55 | - |
|  | 2004-2008 | 86.0 | 100.0 | 51 | 52.0 | 37 | 58 | - |
|  | 1989-2008 | 85.0 | 87.0 | 66 | 49.0 | 35 | 57 | - |

***Note***:-, No report or nonavailable in the original article.

\* indicates statistically significant differences at different times in the original article.

+ indicates statistically significant differences between different groups (different pathology) in the original article.

# 

# **Supplementary Table S11**: Pathology-specific 5-year relative/net survival rates (%) of ovarian cancer in selected countries and regions during 1982-2016

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Country** | **Regions** | **Period** | **All epithelial** | **Serous** | **Mucinous** | **Endometrioid** | **Clear cell** | **Epithelial, Not Otherwise Specified** | **Others** | **Germ cell** | **Sex cord-stromal** | **Mesenchymal** |
| China | Hong Kong52+ | 1997-2006 | 63.1 | 44.6 | 86.0 | 77.8 | 69.4 | 31.7 | - | - | - | - |
| French19, 41+ |  | 1982-2005 |  | 41.0 | 49.0 | | - | - | 31.0 | 63.0 | | |
|  |  | 1989-2010 | 42 | - | - | - | - | - | 39.4 | 82.0 | 47.0 | - |
| Netherlands53\* |  | 1989-1993 | 34.7 | 37.3 | 58.1 | 52.8 | - | 19.3 | 43.0 | - | - | - |
|  |  | 1994-1998 | 36.0 | 36.8 | 56.7 | 59.7 | - | 20.8 | 34.8 | - | - | - |
|  |  | 1999-2003 | 40.0 | 37.6 | 62.4 | 67.7 | - | 24.6 | 39.4 | - | - | - |
|  |  | 2004-2009 | 41.1 | 38.5 | 64.1 | 69.9 | - | 21.4 | 42.2 | - | - | - |
|  | Maastricht40 | 1986-1992 | 36.0 | 37.0 | 59.0 | 65.0 | 56.0 | 22.0 | - | - | - | - |
| Korea44, 54+ |  | 1993-2002 | 58.3 | - | - | - | - | - | - | 89.0 | 90.0 | - |
|  |  | 1997-2016 | - | 57.4 | 76.3 | 78.4 | 75.1 | - | 40.6 | - | - | - |
| United States | Missouri46 | 1996-2014 | - | 40.6 | 68.4 | 78.5 | 68.5 | 26.1 | 23.9 | - | - | - |
| Denmark55 |  | 1988–1997 | - | - | - | - | - | - | - | 79.0 | 80.0 | 45.0 |
|  |  | 1998–2007 | - | - | - | - | - | - | - | 78.0 | 90.0 | 58.0 |
|  |  | 2008–2016 | - | - | - | - | - | - | - | 94.0 | 79.0 | 31.0 |
| Sweden43 |  | 2009-2013 | - | 40.0 | - | - | - | - | - | - | - | - |
| Japan | Osaka56 | 1985-1994 | - | 39.6 | 66.3 | - | - | 24.1 | 15.8 | 69.8 | 46.3 | - |
| Turkey26+ |  | 2009 | - | - | 41.0 | - | - | - | 58.0 | - | - | - |

***Not*e**:-, No report or nonavailable in the original article.

\* indicates statistically significant differences at different times in the original article.

+ indicates statistically significant differences between different groups (different pathology) in the original article.

**References for supplemental tables:**

1. Jun J, Zhang Y, Chen Y, Ding L, Jianguo C. Analysis of survival rate of cervical cancer patients during 2001-2007 in Qidong City. *Chin J Clin Oncol Rehab.* 2011;18(3).

2. Chen J, R S, Shen Z, et al. Population-based cancer survival: an analysis of 16922 cases. *Chinese Journal of Oncology.* 1998;20(3).

3. Gong W, Luo S, Hu R, et al. Analysis of survival rate of breast, cervical, and ovarian cancer patients during 2005-2010 in Zhejiang province, China. *Chinese Journal of Preventive Medicine.* 2014(5).

4. Lu H, Li L, Cheng Y, et al. Timely Estimates of 5-Year Relative Survival for Patients With Cervical Cancer: A Period Analysis Using Cancer Registry Data From Taizhou, Eastern China. *Frontiers in public health.* 2022;10: 926058. <https://doi.org/10.3389/fpubh.2022.926058>.

5. Yeole BB, Kumar AV, Kurkure A, Sunny L. Population-based survival from cancers of breast, cervix and ovary in women in Mumbai, India. *Asian Pac J Cancer Prev.* 2004;5(3): 308-315.

6. Ioka A, Ito Y, Tsukuma H. Factors relating to poor survival rates of aged cervical cancer patients: A population-based study with the relative survival model in Osaka, Japan. *Asian Pacific Journal of Cancer Prevention.* 2009;10(3): 457-462.

7. Gatta G, Lasota MB, Verdecchia A, Grp EW. Survival of European women with gynaecological tumours, during the period 1978-1989. *European Journal of Cancer.* 1998;34(14): 2218-2225. <https://doi.org/10.1016/s0959-8049(98)00326-8>.

8. Bielska-Lasota M, Inghelmann R, van de Poll-Franse L, Capocaccia R. Trends in cervical cancer survival in Europe, 1983-1994: a population-based study. *Gynecol Oncol.* 2007;105(3): 609-619. <https://doi.org/10.1016/j.ygyno.2007.01.048>.

9. Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. *Eur J Cancer.* 2009;45(6): 931-991. <https://doi.org/10.1016/j.ejca.2008.11.018>.

10. Wenzel HHB, Bekkers RLM, Lemmens V, Van der Aa MA, Nijman HW. No improvement in survival of older women with cervical cancer-A nationwide study. *Eur J Cancer.* 2021;151: 159-167. <https://doi.org/10.1016/j.ejca.2021.04.014>.

11. Levi F, La Vecchia C, Randimbison L, Te VC. Incidence, mortality and survival from invasive cervical cancer in Vaud, Switzerland, 1974-1991. *Ann Oncol.* 1994;5(8): 747-752. <https://doi.org/10.1093/oxfordjournals.annonc.a058980>.

12. Gondos A, Holleczek B, Arndt V, Stegmaier C, Ziegler H, Brenner H. Trends in population-based cancer survival in Germany: to what extent does progress reach older patients? *Annals of Oncology.* 2007;18(7): 1253-1259. <https://doi.org/10.1093/annonc/mdm126>.

13. Ojamaa K, Veerus P, Baburin A, Everaus H, Innos K. Increasing incidence and survival of corpus uteri cancer in Estonia over the past two decades. *Cancer Epidemiology.* 2019;62. <https://doi.org/10.1016/j.canep.2019.101566>.

14. Antunes L, Roche L, José Bento M. Trends in net survival from corpus uteri cancer in six European Latin countries: results from the SUDCAN population-based study. *Eur J Cancer Prev.* 2017;26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study: S100-s106. <https://doi.org/10.1097/cej.0000000000000294>.

15. Brenner H, Stegmaier C, Ziegler H. Trends in survival of patients with ovarian cancer in Saarland, Germany, 1976-1995. *Journal of Cancer Research and Clinical Oncology.* 1999;125(2): 109-113. <https://doi.org/10.1007/s004320050250>.

16. Ries LA. Ovarian cancer. Survival and treatment differences by age. *Cancer.* 1993;71(2 Suppl): 524-529. <https://doi.org/10.1002/cncr.2820710206>.

17. Gatta G, Lasota MB, Verdecchia A. Survival of European women with gynaecological tumours, during the period 1978-1989. EUROCARE Working Group. *Eur J Cancer.* 1998;34(14 Spec No): 2218-2225. <https://doi.org/10.1016/s0959-8049(98)00326-8>.

18. De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study. *Lancet Oncology.* 2014;15(1): 23-34. <https://doi.org/10.1016/s1470-2045(13)70546-1>.

19. Tretarre B, Molinie F, Woronoff AS, et al. Ovarian cancer in France: trends in incidence, mortality and survival, 1980-2012. *Gynecologic Oncology.* 2015;139(2): 324-329. <https://doi.org/10.1016/j.ygyno.2015.09.013>.

20. Kang MJ, Won YJ, Lee JJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2019. *Cancer Research and Treatment.* 2022;54(2): 330-344. <https://doi.org/10.4143/crt.2022.128>.

21. Shin DW, Bae J, Ha J, Jung KW. Conditional relative survival of cervical cancer: a Korean National Cancer Registry Study. *J Gynecol Oncol.* 2021;32(1): e5. <https://doi.org/10.3802/jgo.2021.32.e5>.

22. Yagi A, Ueda Y, Kakuda M, et al. Epidemiologic and Clinical Analysis of Cervical Cancer Using Data from the Population-Based Osaka Cancer Registry. *Cancer Res.* 2019;79(6): 1252-1259. <https://doi.org/10.1158/0008-5472.Can-18-3109>.

23. Matsuda T, Ajiki W, Marugame T, Ioka A, Tsukuma H, Sobue T. Population-based survival of cancer patients diagnosed between 1993 and 1999 in Japan: a chronological and international comparative study. *Jpn J Clin Oncol.* 2011;41(1): 40-51. <https://doi.org/10.1093/jjco/hyq167>.

24. Maláková K, Cabasag CJ, Bardot A, et al. Cancer survival in Thailand from 1997 to 2012: assessing the impact of universal health coverage. *J Cancer Policy.* 2022;34: 100353. <https://doi.org/10.1016/j.jcpo.2022.100353>.

25. Alawadhi E, Al-Awadi A, Elbasmi A, Coleman MP, Allemani C. Cancer Survival by Stage at Diagnosis in Kuwait: A Population-Based Study. *J Oncol.* 2019;2019: 8463195. <https://doi.org/10.1155/2019/8463195>.

26. Gultekin M, Dundar S, Kucukyildiz I, et al. Survival of gynecological cancers in Turkey: where are we at? *J Gynecol Oncol.* 2017;28(6): e85. <https://doi.org/10.3802/jgo.2017.28.e85>.

27. Bielska-Lasota M, Rossi S, Krzyżak M, et al. Reasons for low cervical cancer survival in new accession European Union countries: a EUROCARE-5 study. *Arch Gynecol Obstet.* 2020;301(2): 591-602. <https://doi.org/10.1007/s00404-019-05412-5>.

28. Surveillance Research Program NCI. SEER\*Explorer: An interactive website for SEER cancer statistics.; Accessed 7 Jun 2023.

29. Cheung FY, Mang OW, Law SC. A population-based analysis of incidence, mortality, and stage-specific survival of cervical cancer patients in Hong Kong: 1997-2006. *Hong Kong Med J.* 2011;17(2): 89-95.

30. Chiang CJ, Lo WC, Yang YW, You SL, Chen CJ, Lai MS. Incidence and survival of adult cancer patients in Taiwan, 2002-2012. *J Formos Med Assoc.* 2016;115(12): 1076-1088. <https://doi.org/10.1016/j.jfma.2015.10.011>.

31. Chung HH, Jang MJ, Jung KW, et al. Cervical cancer incidence and survival in Korea: 1993-2002. *International Journal of Gynecological Cancer.* 2006;16(5): 1833-1838. <https://doi.org/10.1111/j.1525-1438.2006.00708.x>.

32. Ojamaa K, Innos K, Baburin A, Everaus H, Veerus P. Trends in cervical cancer incidence and survival in Estonia from 1995 to 2014. *BMC Cancer.* 2018;18(1): 1075. <https://doi.org/10.1186/s12885-018-5006-1>.

33. Pavlík T, Májek O, Büchler T, et al. Trends in stage-specific population-based survival of cancer patients in the Czech Republic in the period 2000-2008. *Cancer Epidemiology.* 2014;38(1): 28-34. <https://doi.org/10.1016/j.canep.2013.11.002>.

34. Ulinskas K, Aleknaviciene B, Smailyte G. Demographic differences in cervical cancer survival in Lithuania. *Central European Journal of Medicine.* 2013;8(1): 16-21. <https://doi.org/10.2478/s11536-012-0051-7>.

35. Shin DW, Jung KW, Ha J, Bae J. Conditional relative survival of patients with endometrial cancer: a Korean National Cancer Registry study. *Journal of Gynecologic Oncology.* 2022;33(2). <https://doi.org/10.3802/jgo.2022.33.e23>.

36. Inoue S, Hosono S, Ito H, et al. Improvement in 5-year relative survival in cancer of the corpus uteri from 1993-2000 to 2001-2006 in Japan. *Journal of Epidemiology.* 2018;28(2): 75-80. <https://doi.org/10.2188/jea.JE20170008>.

37. Yagi A, Ueda Y, Ikeda S, et al. Improved long-term survival of corpus cancer in Japan: a 40-year population-based analysis. *International Journal of Cancer.* 2022;150(2): 232-242. <https://doi.org/10.1002/ijc.33799>.

38. Dickman PW, Hakulinen T, Luostarinen T, et al. Survival of cancer patients in Finland 1955-1994. *Acta Oncol.* 1999;38 Suppl 12: 1-103. <https://doi.org/10.1080/028418699432996>.

39. Vernooij F, Heintz APM, Witteveen PO, van der Heiden-van der Loo M, Coebergh JW, van der Graaf Y. Specialized care and survival of ovarian cancer patients in the Netherlands: nationwide cohort study. *Jnci-Journal of the National Cancer Institute.* 2008;100(6): 399-406. <https://doi.org/10.1093/jnci/djn033>.

40. De Rijke JM, Schouten LJ, Volovics A, Van der Putten H. Age-specific differences in treatment and survival of ovarian cancer patients in the province of Limburg, the Netherlands, 1986-92. *International Journal of Gynecological Cancer.* 1998;8(2): 150-157.

41. Hamidou Z, Causeret S, Dabakuyo TS, et al. Population-based study of ovarian cancer in Cote d'Or: prognostic factors and trends in relative survival rates over the last 20 years. *Bmc Cancer.* 2010;10. <https://doi.org/10.1186/1471-2407-10-622>.

42. Ojamaa K, Veerus P, Baburin A, Everaus H, Innos K. Time trends in ovarian cancer survival in Estonia by age and stage. *International Journal of Gynecological Cancer.* 2017;27(1): 44-49. <https://doi.org/10.1097/igc.0000000000000858>.

43. Dahm-Kähler P, Borgfeldt C, Holmberg E, et al. Population-based study of survival for women with serous cancer of the ovary, fallopian tube, peritoneum or undesignated origin - on behalf of the Swedish gynecological cancer group (SweGCG). *Gynecol Oncol.* 2017;144(1): 167-173. <https://doi.org/10.1016/j.ygyno.2016.10.039>.

44. Shin D, Jung K, Bae J. Conditional relative survival of ovarian cancer: a Korean national cancer registry study. *International Journal of Gynecological Cancer.* 2020;30(SUPPL 3): A87. <https://doi.org/10.1136/ijgc-2020-IGCS.177>.

45. Stewart SL, Harewood R, Matz M, et al. Disparities in ovarian cancer survival in the United States (2001-2009): findings from the CONCORD-2 study. *Cancer.* 2017;123: 5138-5159. <https://doi.org/10.1002/cncr.31027>.

46. Yoshida Y, Schmaltz CL, Jackson-Thompson J, Simoes EJ. Ovarian cancer survival in Missouri, 1996-2014. *Mo Med.* 2018;115(6): 542-547.

47. Bjurberg M, Holmberg E, Borgfeldt C, et al. Primary treatment patterns and survival of cervical cancer in Sweden: A population-based Swedish Gynecologic Cancer Group Study. *Gynecol Oncol.* 2019;155(2): 229-236. <https://doi.org/10.1016/j.ygyno.2019.08.022>.

48. Emmett M, Gildea C, Nordin A, Hirschowitz L, Poole J. Cervical cancer - does the morphological subtype affect survival rates? *J Obstet Gynaecol.* 2018;38(4): 548-555. <https://doi.org/10.1080/01443615.2017.1379062>.

49. Gari A, Lotocki R, Krepart G, Popowich S, Demers A. Cervical Cancer in the Province of Manitoba: A 30-Year Experience. *Journal of Obstetrics and Gynaecology Canada.* 2008;30(9): 788-795. <https://doi.org/10.1016/S1701-2163(16)32943-7>.

50. Bjorge T, Thoresen SO, Skare GB. Incidence, survival and mortality in cervical cancer in Norway, 1956-1990. *European Journal of Cancer Part A: General Topics.* 1993;29(16): 2291-2297. <https://doi.org/10.1016/0959-8049(93)90224-4>.

51. Boll D, Verhoeven RH, van der Aa MA, et al. Incidence and survival trends of uncommon corpus uteri malignancies in the Netherlands, 1989-2008. *Int J Gynecol Cancer.* 2012;22(4): 599-606. <https://doi.org/10.1097/IGC.0b013e318244cedc>.

52. Wong KH, Mang OWK, Au KH, Law SCK. Incidence, mortality, and survival trends of ovarian cancer in Hong Kong, 1997 to 2006: a population-based study. *Hong Kong Medical Journal.* 2012;18(6): 466-474.

53. van Altena AM, Karim-Kos HE, de Vries E, Kruitwagen RF, Massuger LF, Kiemeney LA. Trends in therapy and survival of advanced stage epithelial ovarian cancer patients in the Netherlands. *Gynecol Oncol.* 2012;125(3): 649-654. <https://doi.org/10.1016/j.ygyno.2012.02.033>.

54. Chung HH, Hwang SY, Jung KW, et al. Ovarian cancer incidence and survival in Korea: 1993-2002. *Int J Gynecol Cancer.* 2007;17(3): 595-600. <https://doi.org/10.1111/j.1525-1438.2007.00824.x>.

55. Bennetsen AKK, Baandrup L, Aalborg GL, Kjaer SK. Non-epithelial ovarian cancer in Denmark - Incidence and survival over nearly 40 years. *Gynecologic Oncology.* 2020;157(3): 693-699. <https://doi.org/10.1016/j.ygyno.2020.03.021>.

56. Ioka A, Tsukuma H, Ajiki W, Oshima A. Ovarian cancer incidence and survival by histologic type in Osaka, Japan. *Cancer Science.* 2003;94(3): 292-296.